Home > Press Releases > AI-Powered Drug Discovery Market

AI-Powered Drug Discovery Market Likely to Surpass ~USD 9 billion by 2035

Report Code: HC-26986  |  Published in: Mar 2026, By MarketGenics  |  Number of pages: 333

Global AI-Powered Drug Discovery Market Forecast 2035:

According to the report, the global AI-powered drug discovery market is likely to grow from USD 1 Billion in 2025 to USD 9.2 Billion in 2035 at a highest CAGR of 24.6% during the time period. The AI-powered drug discovery market is currently experiencing rapid growth because of three factors which include the need to shorten research and development timeframes and the increasing expenses of drug development processes and the requirement to enhance clinical trial success rates.

Pharmaceutical and biotechnology companies are now using AI-based platforms which help them analyze complicated biological and clinical and multi-omics data sets to improve their target identification and lead optimization and predictive modeling processes, which results in better accuracy and higher productivity and better decision-making abilities. The implementation of government programs together with public and private organization partnerships which focus on precision medicine and rare disease research will drive faster adoption of these technologies.

The biopharma sector uses artificial intelligence to create more efficient methods for molecule design and toxicity prediction and clinical candidate selection. The combination of artificial intelligence (AI) and machine learning (ML) with high-performance computing technology provides improved predictive capabilities and scalability for drug development processes.

The development of cloud-based artificial intelligence platforms together with generative models enables pharmaceutical researchers to conduct real-time simulations and virtual compound screenings, which leads to more efficient and affordable drug discovery processes that benefit healthcare systems worldwide.

Key Driver, Restraint, and Growth Opportunity Shaping the Global AI-Powered Drug Discovery Market

The global AI-powered drug discovery market experiences growth because research organizations now use AI platforms for their early-stage research work which involves target identification and molecule generation and clinical candidate selection. Pharmaceutical companies use AI technology to examine extensive biological data and real-world information which enables them to achieve better results while decreasing their product development time.

For instance, the Recursion Pharmaceuticals and Roche partnership expanded its AI-based research operations for target discovery and validation because both companies required AI technology to enhance their drug development operations.

The biological data complexity along with the fragmented genomic and proteomic and clinical record datasets creates ongoing challenges for research purposes. The existing data quality differences together with missing standardization and the challenges in verifying AI output results cause AI systems to experience problems with both scaling operations and achieving dependable performance.

The process of integrating AI technologies into conventional drug discovery methods requires organizations to invest in new infrastructure while acquiring special knowledge which results in higher operating expenses and delayed adoption of these technologies particularly for smaller biotech companies.

Artificial intelligence presents a significant opportunity in precision medicine and rare disease research because traditional research methods struggle to handle small patient groups and complicated disease patterns. AI technology allows researchers to discover new biomarkers and develop specific treatment methods at a faster speed. Schrödinger and other companies use AI-driven physics-based modeling to develop targeted therapies which create new possibilities for personalized medicine development and improve innovation capacity in areas that need it most.

Expansion of Global AI-Powered Drug Discovery Market

Technological Innovation, Biopharma Applications, and R&D Investments Driving the Global AIPowered Drug Discovery Market Expansion

  • The combination of technological innovation, broad applications of biopharma, and increasing investments in R&D are driving rapid growth of the global AI-based drug discovery market technologies. The application of advanced forms of machine learning (ML), deep learning (DL), and Generative-AI (GAI) into drug discovery processes has enabled improved speed of target identification, predictive modeling, and lead optimization through dramatic reductions in the amount of time and cost for traditional drug development.
  • For example, Lilly’s partnership with NVIDIA to establish a USD 1 billion AI co-innovation lab for the purpose of creating dedicated supercomputing infrastructure for developing AI models across all phases of drug development represents a significant investment in cutting-edge technologies.
  • On a similar note, the Bahrain Sovereign Fund’s partnership with SandboxAQ to accelerate the development of therapeutics using AI further illustrates how these technologies are being utilized beyond their traditional hubs in the biopharmaceutical industry around the world.
  • Additionally, many large pharmaceutical companies are significantly increasing their computing capacity as part of their investment in advanced technologies. For example, Roche has over 2100 Nvidia GPUs deployed to enhance its research and modeling efforts around AI. Ultimately, investing in technology to create improved infrastructure to support R&D productivity has broad implications for increasing innovation rate throughout both preclinical and clinical developments across the pharmaceutical industry.

Regional Analysis of Global AI-Powered Drug Discovery Market

  • North America holds the top position in the global AI-powered drug discovery market because it has an established digital health system and a large number of biotech and pharmaceutical companies and it invests heavily in research and development. The United States operates excellent AI-based drug discovery systems because it receives substantial financial support while maintaining strict regulations for clinical data and having established partnerships between pharmaceutical companies and AI developers.
  • The local market leadership receives support from Lilly's partnership with NVIDIA which develops AI-based supercomputing systems to improve target identification and lead optimization processes.
  • The Asia Pacific region currently experiences the fastest growth rate in AI-based drug discovery because healthcare digitalization progresses while biotech and pharmaceutical companies invest more and organizations start using AI-based research and development solutions.
  • India and China expand their artificial intelligence programs through partnerships with both international pharmaceutical companies and local startup businesses. The increasing regional capabilities become evident through Bharat Biotech's artificial intelligence vaccine development programs in India. The Asian Pacific region experiences double-digit growth in artificial intelligence-driven drug discovery because of its cloud infrastructure and government initiatives that support innovation.

Prominent players operating in global AI-powered drug discovery market include prominent companies such as Atomwise, Inc., BenevolentAI Limited, Berg LLC, BioXcel Therapeutics, Inc., Cyclica Inc., Deep Genomics Inc., Exscientia plc, Healx Limited, Iktos S.A., Insilico Medicine, Inc., Insitro, Inc., Lantern Pharma Inc., Numerate, Inc., Owkin, Inc., Recursion Pharmaceuticals, Inc., Schrödinger, Inc., Standigm Inc., Valo Health, Inc., Verge Genomics, Inc., XtalPi Inc., along with several other key players.

The global AI-powered drug discovery market has been segmented as follows:

Global AI-Powered Drug Discovery Market Analysis, by Offering

  • Software Platforms
  • AI Algorithms and Models
  • Cloud-Based Drug Discovery Platforms
  • Data Analytics Platforms
  • Services

Global AI-Powered Drug Discovery Market Analysis, by Technology

  • Machine Learning (ML)
  • Deep Learning
  • Natural Language Processing (NLP)
  • Computer Vision
  • Reinforcement Learning
  • Generative AI Models
  • Others

Global AI-Powered Drug Discovery Market Analysis, by Drug Type

  • Small Molecules
  • Large Molecules / Biologics
  • Gene Therapy-Based Drugs
  • RNA-Based Therapeutics
  • Others

Global AI-Powered Drug Discovery Market Analysis, by Discovery Stage

  • Target Identification and Validation
  • Hit Identification / Screening
  • Hit-to-Lead Optimization
  • Lead Optimization
  • Preclinical Testing
  • Others

Global AI-Powered Drug Discovery Market Analysis, by Therapeutic Area

  • Oncology
  • Neurology and Neurodegenerative Diseases
  • Cardiovascular Diseases
  • Infectious Diseases
  • Metabolic Disorders
  • Immunology and Autoimmune Diseases
  • Respiratory Disorders
  • Rare Diseases
  • Others

Global AI-Powered Drug Discovery Market Analysis, by Deployment Mode

  • Cloud-Based Platforms
  • On-Premise Platforms
  • Hybrid Deployment

Global AI-Powered Drug Discovery Market Analysis, by Data Type

  • Genomics Data
  • Proteomics Data
  • Clinical Trial Data
  • Chemical Structure Data
  • Real-World Data (RWD)
  • Others

Global AI-Powered Drug Discovery Market Analysis, by Application

  • Target Identification
  • Drug Repurposing
  • De Novo Drug Design
  • Virtual Screening
  • Biomarker Discovery
  • Toxicity Prediction
  • Pharmacokinetics and ADMET Prediction
  • Others

Global AI-Powered Drug Discovery Market Analysis, by End User

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic and Research Institutes
  • Healthcare AI Startups
  • Others

Global AI-Powered Drug Discovery Market Analysis, by Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Natures
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Natures
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global AI-Powered Drug Discovery Market Outlook
      • 2.1.1. AI-Powered Drug Discovery Market Size (Value - US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2026-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
      • 3.1.1. Healthcare & Pharmaceutical Industry Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
    • 3.4. Trade Analysis
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Growing adoption of decentralized and remote healthcare solutions.
        • 4.1.1.2. Increased need for faster and cost-effective clinical trial processes.
        • 4.1.1.3. Rising prevalence of chronic diseases boosting demand for patient-centric trials.
      • 4.1.2. Restraints
        • 4.1.2.1. Data privacy and cybersecurity concerns in handling patient information.
        • 4.1.2.2. Limited technological infrastructure in emerging markets restricting adoption.
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Value Chain Analysis
    • 4.5. Cost Structure Analysis
    • 4.6. Porter’s Five Forces Analysis
    • 4.7. PESTEL Analysis
    • 4.8. Global AI-Powered Drug Discovery Market Demand
      • 4.8.1. Historical Market Size – Value (US$ Bn), 2020-2024
      • 4.8.2. Current and Future Market Size – Value (US$ Bn), 2026–2035
        • 4.8.2.1. Y-o-Y Growth Trends
        • 4.8.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global AI-Powered Drug Discovery Market Analysis, by Offering
    • 6.1. Key Segment Analysis
    • 6.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by Offering, 2021-2035
      • 6.2.1. Software Platforms
      • 6.2.2. AI Algorithms and Models
      • 6.2.3. Cloud-Based Drug Discovery Platforms
      • 6.2.4. Data Analytics Platforms
      • 6.2.5. Services
  • 7. Global AI-Powered Drug Discovery Market Analysis, by Technological
    • 7.1. Key Segment Analysis
    • 7.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by Technological, 2021-2035
      • 7.2.1. Machine Learning (ML)
      • 7.2.2. Deep Learning
      • 7.2.3. Natural Language Processing (NLP)
      • 7.2.4. Computer Vision
      • 7.2.5. Reinforcement Learning
      • 7.2.6. Generative AI Models
      • 7.2.7. Others
  • 8. Global AI-Powered Drug Discovery Market Analysis, by Drug Type
    • 8.1. Key Segment Analysis
    • 8.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by Drug Type, 2021-2035
      • 8.2.1. Small Molecules
      • 8.2.2. Large Molecules / Biologics
      • 8.2.3. Gene Therapy-Based Drugs
      • 8.2.4. RNA-Based Therapeutics
      • 8.2.5. Others
  • 9. Global AI-Powered Drug Discovery Market Analysis, by Discovery Stage
    • 9.1. Key Segment Analysis
    • 9.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by Discovery Stage, 2021-2035
      • 9.2.1. Target Identification and Validation
      • 9.2.2. Hit Identification / Screening
      • 9.2.3. Hit-to-Lead Optimization
      • 9.2.4. Lead Optimization
      • 9.2.5. Preclinical Testing
      • 9.2.6. Others
  • 10. Global AI-Powered Drug Discovery Market Analysis, by Therapeutic Area
    • 10.1. Key Segment Analysis
    • 10.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapeutic Area, 2021-2035
      • 10.2.1. Oncology
      • 10.2.2. Neurology and Neurodegenerative Diseases
      • 10.2.3. Cardiovascular Diseases
      • 10.2.4. Infectious Diseases
      • 10.2.5. Metabolic Disorders
      • 10.2.6. Immunology and Autoimmune Diseases
      • 10.2.7. Respiratory Disorders
      • 10.2.8. Rare Diseases
      • 10.2.9. Others
  • 11. Global AI-Powered Drug Discovery Market Analysis, by Deployment Mode
    • 11.1. Key Segment Analysis
    • 11.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by Deployment Mode, 2021-2035
      • 11.2.1. Cloud-Based Platforms
      • 11.2.2. On-Premise Platforms
      • 11.2.3. Hybrid Deployment
  • 12. Global AI-Powered Drug Discovery Market Analysis, by Data Type
    • 12.1. Key Segment Analysis
    • 12.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by Data Type, 2021-2035
      • 12.2.1. Genomics Data
      • 12.2.2. Proteomics Data
      • 12.2.3. Clinical Trial Data
      • 12.2.4. Chemical Structure Data
      • 12.2.5. Real-World Data (RWD)
      • 12.2.6. Others
  • 13. Global AI-Powered Drug Discovery Market Analysis, by Application
    • 13.1. Key Segment Analysis
    • 13.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by Application, 2021-2035
      • 13.2.1. Target Identification
      • 13.2.2. Drug Repurposing
      • 13.2.3. De Novo Drug Design
      • 13.2.4. Virtual Screening
      • 13.2.5. Biomarker Discovery
      • 13.2.6. Toxicity Prediction
      • 13.2.7. Pharmacokinetics and ADMET Prediction
      • 13.2.8. Others
  • 14. Global AI-Powered Drug Discovery Market Analysis, by End User
    • 14.1. Key Segment Analysis
    • 14.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by End User, 2021-2035
      • 14.2.1. Pharmaceutical Companies
      • 14.2.2. Biotechnology Companies
      • 14.2.3. Contract Research Organizations (CROs)
      • 14.2.4. Academic and Research Institutes
      • 14.2.5. Healthcare AI Startups
      • 14.2.6. Others
  • 15. Global AI-Powered Drug Discovery Market Analysis and Forecasts, by Region
    • 15.1. Key Findings
    • 15.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
      • 15.2.1. North America
      • 15.2.2. Europe
      • 15.2.3. Asia Pacific
      • 15.2.4. Middle East
      • 15.2.5. Africa
      • 15.2.6. South America
  • 16. North America AI-Powered Drug Discovery Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. North America AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Offering
      • 16.3.2. Technological
      • 16.3.3. Drug Type
      • 16.3.4. Discovery Stage
      • 16.3.5. Therapeutic Area
      • 16.3.6. Deployment Mode
      • 16.3.7. Data Type
      • 16.3.8. Application
      • 16.3.9. End User
      • 16.3.10. Country
        • 16.3.10.1. USA
        • 16.3.10.2. Canada
        • 16.3.10.3. Mexico
    • 16.4. USA AI-Powered Drug Discovery Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Offering
      • 16.4.3. Technological
      • 16.4.4. Drug Type
      • 16.4.5. Discovery Stage
      • 16.4.6. Therapeutic Area
      • 16.4.7. Deployment Mode
      • 16.4.8. Data Type
      • 16.4.9. Application
      • 16.4.10. End User
    • 16.5. Canada AI-Powered Drug Discovery Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Offering
      • 16.5.3. Technological
      • 16.5.4. Drug Type
      • 16.5.5. Discovery Stage
      • 16.5.6. Therapeutic Area
      • 16.5.7. Deployment Mode
      • 16.5.8. Data Type
      • 16.5.9. Application
      • 16.5.10. End User
    • 16.6. Mexico AI-Powered Drug Discovery Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Offering
      • 16.6.3. Technological
      • 16.6.4. Drug Type
      • 16.6.5. Discovery Stage
      • 16.6.6. Therapeutic Area
      • 16.6.7. Deployment Mode
      • 16.6.8. Data Type
      • 16.6.9. Application
      • 16.6.10. End User
  • 17. Europe AI-Powered Drug Discovery Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Europe AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Offering
      • 17.3.2. Technological
      • 17.3.3. Drug Type
      • 17.3.4. Discovery Stage
      • 17.3.5. Therapeutic Area
      • 17.3.6. Deployment Mode
      • 17.3.7. Data Type
      • 17.3.8. Application
      • 17.3.9. End User
      • 17.3.10. Country
        • 17.3.10.1. Germany
        • 17.3.10.2. United Kingdom
        • 17.3.10.3. France
        • 17.3.10.4. Italy
        • 17.3.10.5. Spain
        • 17.3.10.6. Netherlands
        • 17.3.10.7. Nordic Countries
        • 17.3.10.8. Poland
        • 17.3.10.9. Russia & CIS
        • 17.3.10.10. Rest of Europe
    • 17.4. Germany AI-Powered Drug Discovery Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Offering
      • 17.4.3. Technological
      • 17.4.4. Drug Type
      • 17.4.5. Discovery Stage
      • 17.4.6. Therapeutic Area
      • 17.4.7. Deployment Mode
      • 17.4.8. Data Type
      • 17.4.9. Application
      • 17.4.10. End User
    • 17.5. United Kingdom AI-Powered Drug Discovery Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Offering
      • 17.5.3. Technological
      • 17.5.4. Drug Type
      • 17.5.5. Discovery Stage
      • 17.5.6. Therapeutic Area
      • 17.5.7. Deployment Mode
      • 17.5.8. Data Type
      • 17.5.9. Application
      • 17.5.10. End User
    • 17.6. France AI-Powered Drug Discovery Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Offering
      • 17.6.3. Technological
      • 17.6.4. Drug Type
      • 17.6.5. Discovery Stage
      • 17.6.6. Therapeutic Area
      • 17.6.7. Deployment Mode
      • 17.6.8. Data Type
      • 17.6.9. Application
      • 17.6.10. End User
    • 17.7. Italy AI-Powered Drug Discovery Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Offering
      • 17.7.3. Technological
      • 17.7.4. Drug Type
      • 17.7.5. Discovery Stage
      • 17.7.6. Therapeutic Area
      • 17.7.7. Deployment Mode
      • 17.7.8. Data Type
      • 17.7.9. Application
      • 17.7.10. End User
    • 17.8. Spain AI-Powered Drug Discovery Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Offering
      • 17.8.3. Technological
      • 17.8.4. Drug Type
      • 17.8.5. Discovery Stage
      • 17.8.6. Therapeutic Area
      • 17.8.7. Deployment Mode
      • 17.8.8. Data Type
      • 17.8.9. Application
      • 17.8.10. End User
    • 17.9. Netherlands AI-Powered Drug Discovery Market
      • 17.9.1. Country Segmental Analysis
      • 17.9.2. Offering
      • 17.9.3. Technological
      • 17.9.4. Drug Type
      • 17.9.5. Discovery Stage
      • 17.9.6. Therapeutic Area
      • 17.9.7. Deployment Mode
      • 17.9.8. Data Type
      • 17.9.9. Application
      • 17.9.10. End User
    • 17.10. Nordic Countries AI-Powered Drug Discovery Market
      • 17.10.1. Country Segmental Analysis
      • 17.10.2. Offering
      • 17.10.3. Technological
      • 17.10.4. Drug Type
      • 17.10.5. Discovery Stage
      • 17.10.6. Therapeutic Area
      • 17.10.7. Deployment Mode
      • 17.10.8. Data Type
      • 17.10.9. Application
      • 17.10.10. End User
    • 17.11. Poland AI-Powered Drug Discovery Market
      • 17.11.1. Country Segmental Analysis
      • 17.11.2. Offering
      • 17.11.3. Technological
      • 17.11.4. Drug Type
      • 17.11.5. Discovery Stage
      • 17.11.6. Therapeutic Area
      • 17.11.7. Deployment Mode
      • 17.11.8. Data Type
      • 17.11.9. Application
      • 17.11.10. End User
    • 17.12. Russia & CIS AI-Powered Drug Discovery Market
      • 17.12.1. Country Segmental Analysis
      • 17.12.2. Offering
      • 17.12.3. Technological
      • 17.12.4. Drug Type
      • 17.12.5. Discovery Stage
      • 17.12.6. Therapeutic Area
      • 17.12.7. Deployment Mode
      • 17.12.8. Data Type
      • 17.12.9. Application
      • 17.12.10. End User
    • 17.13. Rest of Europe AI-Powered Drug Discovery Market
      • 17.13.1. Country Segmental Analysis
      • 17.13.2. Offering
      • 17.13.3. Technological
      • 17.13.4. Drug Type
      • 17.13.5. Discovery Stage
      • 17.13.6. Therapeutic Area
      • 17.13.7. Deployment Mode
      • 17.13.8. Data Type
      • 17.13.9. Application
      • 17.13.10. End User
  • 18. Asia Pacific AI-Powered Drug Discovery Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. Asia Pacific AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Offering
      • 18.3.2. Technological
      • 18.3.3. Drug Type
      • 18.3.4. Discovery Stage
      • 18.3.5. Therapeutic Area
      • 18.3.6. Deployment Mode
      • 18.3.7. Data Type
      • 18.3.8. Application
      • 18.3.9. End User
      • 18.3.10. Country
        • 18.3.10.1. China
        • 18.3.10.2. India
        • 18.3.10.3. Japan
        • 18.3.10.4. South Korea
        • 18.3.10.5. Australia and New Zealand
        • 18.3.10.6. Indonesia
        • 18.3.10.7. Malaysia
        • 18.3.10.8. Thailand
        • 18.3.10.9. Vietnam
        • 18.3.10.10. Rest of Asia Pacific
    • 18.4. China AI-Powered Drug Discovery Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Offering
      • 18.4.3. Technological
      • 18.4.4. Drug Type
      • 18.4.5. Discovery Stage
      • 18.4.6. Therapeutic Area
      • 18.4.7. Deployment Mode
      • 18.4.8. Data Type
      • 18.4.9. Application
      • 18.4.10. End User
    • 18.5. India AI-Powered Drug Discovery Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Offering
      • 18.5.3. Technological
      • 18.5.4. Drug Type
      • 18.5.5. Discovery Stage
      • 18.5.6. Therapeutic Area
      • 18.5.7. Deployment Mode
      • 18.5.8. Data Type
      • 18.5.9. Application
      • 18.5.10. End User
    • 18.6. Japan AI-Powered Drug Discovery Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Offering
      • 18.6.3. Technological
      • 18.6.4. Drug Type
      • 18.6.5. Discovery Stage
      • 18.6.6. Therapeutic Area
      • 18.6.7. Deployment Mode
      • 18.6.8. Data Type
      • 18.6.9. Application
      • 18.6.10. End User
    • 18.7. South Korea AI-Powered Drug Discovery Market
      • 18.7.1. Country Segmental Analysis
      • 18.7.2. Offering
      • 18.7.3. Technological
      • 18.7.4. Drug Type
      • 18.7.5. Discovery Stage
      • 18.7.6. Therapeutic Area
      • 18.7.7. Deployment Mode
      • 18.7.8. Data Type
      • 18.7.9. Application
      • 18.7.10. End User
    • 18.8. Australia and New Zealand AI-Powered Drug Discovery Market
      • 18.8.1. Country Segmental Analysis
      • 18.8.2. Offering
      • 18.8.3. Technological
      • 18.8.4. Drug Type
      • 18.8.5. Discovery Stage
      • 18.8.6. Therapeutic Area
      • 18.8.7. Deployment Mode
      • 18.8.8. Data Type
      • 18.8.9. Application
      • 18.8.10. End User
    • 18.9. Indonesia AI-Powered Drug Discovery Market
      • 18.9.1. Country Segmental Analysis
      • 18.9.2. Offering
      • 18.9.3. Technological
      • 18.9.4. Drug Type
      • 18.9.5. Discovery Stage
      • 18.9.6. Therapeutic Area
      • 18.9.7. Deployment Mode
      • 18.9.8. Data Type
      • 18.9.9. Application
      • 18.9.10. End User
    • 18.10. Malaysia AI-Powered Drug Discovery Market
      • 18.10.1. Country Segmental Analysis
      • 18.10.2. Offering
      • 18.10.3. Technological
      • 18.10.4. Drug Type
      • 18.10.5. Discovery Stage
      • 18.10.6. Therapeutic Area
      • 18.10.7. Deployment Mode
      • 18.10.8. Data Type
      • 18.10.9. Application
      • 18.10.10. End User
    • 18.11. Thailand AI-Powered Drug Discovery Market
      • 18.11.1. Country Segmental Analysis
      • 18.11.2. Offering
      • 18.11.3. Technological
      • 18.11.4. Drug Type
      • 18.11.5. Discovery Stage
      • 18.11.6. Therapeutic Area
      • 18.11.7. Deployment Mode
      • 18.11.8. Data Type
      • 18.11.9. Application
      • 18.11.10. End User
    • 18.12. Vietnam AI-Powered Drug Discovery Market
      • 18.12.1. Country Segmental Analysis
      • 18.12.2. Offering
      • 18.12.3. Technological
      • 18.12.4. Drug Type
      • 18.12.5. Discovery Stage
      • 18.12.6. Therapeutic Area
      • 18.12.7. Deployment Mode
      • 18.12.8. Data Type
      • 18.12.9. Application
      • 18.12.10. End User
    • 18.13. Rest of Asia Pacific AI-Powered Drug Discovery Market
      • 18.13.1. Country Segmental Analysis
      • 18.13.2. Offering
      • 18.13.3. Technological
      • 18.13.4. Drug Type
      • 18.13.5. Discovery Stage
      • 18.13.6. Therapeutic Area
      • 18.13.7. Deployment Mode
      • 18.13.8. Data Type
      • 18.13.9. Application
      • 18.13.10. End User
  • 19. Middle East AI-Powered Drug Discovery Market Analysis
    • 19.1. Key Segment Analysis
    • 19.2. Regional Snapshot
    • 19.3. Middle East AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 19.3.1. Offering
      • 19.3.2. Technological
      • 19.3.3. Drug Type
      • 19.3.4. Discovery Stage
      • 19.3.5. Therapeutic Area
      • 19.3.6. Deployment Mode
      • 19.3.7. Data Type
      • 19.3.8. Application
      • 19.3.9. End User
      • 19.3.10. Country
        • 19.3.10.1. Turkey
        • 19.3.10.2. UAE
        • 19.3.10.3. Saudi Arabia
        • 19.3.10.4. Israel
        • 19.3.10.5. Rest of Middle East
    • 19.4. Turkey AI-Powered Drug Discovery Market
      • 19.4.1. Country Segmental Analysis
      • 19.4.2. Offering
      • 19.4.3. Technological
      • 19.4.4. Drug Type
      • 19.4.5. Discovery Stage
      • 19.4.6. Therapeutic Area
      • 19.4.7. Deployment Mode
      • 19.4.8. Data Type
      • 19.4.9. Application
      • 19.4.10. End User
    • 19.5. UAE AI-Powered Drug Discovery Market
      • 19.5.1. Country Segmental Analysis
      • 19.5.2. Offering
      • 19.5.3. Technological
      • 19.5.4. Drug Type
      • 19.5.5. Discovery Stage
      • 19.5.6. Therapeutic Area
      • 19.5.7. Deployment Mode
      • 19.5.8. Data Type
      • 19.5.9. Application
      • 19.5.10. End User
    • 19.6. Saudi Arabia AI-Powered Drug Discovery Market
      • 19.6.1. Country Segmental Analysis
      • 19.6.2. Offering
      • 19.6.3. Technological
      • 19.6.4. Drug Type
      • 19.6.5. Discovery Stage
      • 19.6.6. Therapeutic Area
      • 19.6.7. Deployment Mode
      • 19.6.8. Data Type
      • 19.6.9. Application
      • 19.6.10. End User
    • 19.7. Israel AI-Powered Drug Discovery Market
      • 19.7.1. Country Segmental Analysis
      • 19.7.2. Offering
      • 19.7.3. Technological
      • 19.7.4. Drug Type
      • 19.7.5. Discovery Stage
      • 19.7.6. Therapeutic Area
      • 19.7.7. Deployment Mode
      • 19.7.8. Data Type
      • 19.7.9. Application
      • 19.7.10. End User
    • 19.8. Rest of Middle East AI-Powered Drug Discovery Market
      • 19.8.1. Country Segmental Analysis
      • 19.8.2. Offering
      • 19.8.3. Technological
      • 19.8.4. Drug Type
      • 19.8.5. Discovery Stage
      • 19.8.6. Therapeutic Area
      • 19.8.7. Deployment Mode
      • 19.8.8. Data Type
      • 19.8.9. Application
      • 19.8.10. End User
  • 20. Africa AI-Powered Drug Discovery Market Analysis
    • 20.1. Key Segment Analysis
    • 20.2. Regional Snapshot
    • 20.3. Africa AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 20.3.1. Offering
      • 20.3.2. Technological
      • 20.3.3. Drug Type
      • 20.3.4. Discovery Stage
      • 20.3.5. Therapeutic Area
      • 20.3.6. Deployment Mode
      • 20.3.7. Data Type
      • 20.3.8. Application
      • 20.3.9. End User
      • 20.3.10. Country
        • 20.3.10.1. South Africa
        • 20.3.10.2. Egypt
        • 20.3.10.3. Nigeria
        • 20.3.10.4. Algeria
        • 20.3.10.5. Rest of Africa
    • 20.4. South Africa AI-Powered Drug Discovery Market
      • 20.4.1. Country Segmental Analysis
      • 20.4.2. Offering
      • 20.4.3. Technological
      • 20.4.4. Drug Type
      • 20.4.5. Discovery Stage
      • 20.4.6. Therapeutic Area
      • 20.4.7. Deployment Mode
      • 20.4.8. Data Type
      • 20.4.9. Application
      • 20.4.10. End User
    • 20.5. Egypt AI-Powered Drug Discovery Market
      • 20.5.1. Country Segmental Analysis
      • 20.5.2. Offering
      • 20.5.3. Technological
      • 20.5.4. Drug Type
      • 20.5.5. Discovery Stage
      • 20.5.6. Therapeutic Area
      • 20.5.7. Deployment Mode
      • 20.5.8. Data Type
      • 20.5.9. Application
      • 20.5.10. End User
    • 20.6. Nigeria AI-Powered Drug Discovery Market
      • 20.6.1. Country Segmental Analysis
      • 20.6.2. Offering
      • 20.6.3. Technological
      • 20.6.4. Drug Type
      • 20.6.5. Discovery Stage
      • 20.6.6. Therapeutic Area
      • 20.6.7. Deployment Mode
      • 20.6.8. Data Type
      • 20.6.9. Application
      • 20.6.10. End User
    • 20.7. Algeria AI-Powered Drug Discovery Market
      • 20.7.1. Country Segmental Analysis
      • 20.7.2. Offering
      • 20.7.3. Technological
      • 20.7.4. Drug Type
      • 20.7.5. Discovery Stage
      • 20.7.6. Therapeutic Area
      • 20.7.7. Deployment Mode
      • 20.7.8. Data Type
      • 20.7.9. Application
      • 20.7.10. End User
    • 20.8. Rest of Africa AI-Powered Drug Discovery Market
      • 20.8.1. Country Segmental Analysis
      • 20.8.2. Offering
      • 20.8.3. Technological
      • 20.8.4. Drug Type
      • 20.8.5. Discovery Stage
      • 20.8.6. Therapeutic Area
      • 20.8.7. Deployment Mode
      • 20.8.8. Data Type
      • 20.8.9. Application
      • 20.8.10. End User
  • 21. South America AI-Powered Drug Discovery Market Analysis
    • 21.1. Key Segment Analysis
    • 21.2. Regional Snapshot
    • 21.3. South America AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 21.3.1. Offering
      • 21.3.2. Technological
      • 21.3.3. Drug Type
      • 21.3.4. Discovery Stage
      • 21.3.5. Therapeutic Area
      • 21.3.6. Deployment Mode
      • 21.3.7. Data Type
      • 21.3.8. Application
      • 21.3.9. End User
      • 21.3.10. Country
        • 21.3.10.1. Brazil
        • 21.3.10.2. Argentina
        • 21.3.10.3. Rest of South America
    • 21.4. Brazil AI-Powered Drug Discovery Market
      • 21.4.1. Country Segmental Analysis
      • 21.4.2. Offering
      • 21.4.3. Technological
      • 21.4.4. Drug Type
      • 21.4.5. Discovery Stage
      • 21.4.6. Therapeutic Area
      • 21.4.7. Deployment Mode
      • 21.4.8. Data Type
      • 21.4.9. Application
      • 21.4.10. End User
    • 21.5. Argentina AI-Powered Drug Discovery Market
      • 21.5.1. Country Segmental Analysis
      • 21.5.2. Offering
      • 21.5.3. Technological
      • 21.5.4. Drug Type
      • 21.5.5. Discovery Stage
      • 21.5.6. Therapeutic Area
      • 21.5.7. Deployment Mode
      • 21.5.8. Data Type
      • 21.5.9. Application
      • 21.5.10. End User
    • 21.6. Rest of South America AI-Powered Drug Discovery Market
      • 21.6.1. Country Segmental Analysis
      • 21.6.2. Offering
      • 21.6.3. Technological
      • 21.6.4. Offering
      • 21.6.5. Discovery Stage
      • 21.6.6. Crop Type
      • 21.6.7. Deployment Mode
      • 21.6.8. Data Type
      • 21.6.9. End User
  • 22. Key Players/ Company Profile
    • 22.1. Atomwise, Inc.
      • 22.1.1. Company Details/ Overview
      • 22.1.2. Company Financials
      • 22.1.3. Key Customers and Competitors
      • 22.1.4. Business/ Industry Portfolio
      • 22.1.5. Product Portfolio/ Specification Details
      • 22.1.6. Pricing Data
      • 22.1.7. Strategic Overview
      • 22.1.8. Recent Developments
    • 22.2. BenevolentAI Limited
    • 22.3. Berg LLC
    • 22.4. BioXcel Therapeutics, Inc.
    • 22.5. Cyclica Inc.
    • 22.6. Deep Genomics Inc.
    • 22.7. Exscientia plc
    • 22.8. Healx Limited
    • 22.9. Iktos S.A.
    • 22.10. Insilico Medicine, Inc.
    • 22.11. Insitro, Inc.
    • 22.12. Lantern Pharma Inc.
    • 22.13. Numerate, Inc.
    • 22.14. Owkin, Inc.
    • 22.15. Recursion Pharmaceuticals, Inc.
    • 22.16. Schrödinger, Inc.
    • 22.17. Standigm Inc.
    • 22.18. Valo Health, Inc.
    • 22.19. Verge Genomics, Inc.
    • 22.20. XtalPi Inc.
    • 22.21. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation